77
Participants
Start Date
April 13, 2018
Primary Completion Date
April 21, 2021
Study Completion Date
April 21, 2021
Tislelizumab
Administered intravenously
National Taiwan University Hospital, Taipei
Institut Dhematologie de Basse Normandie Chu Caen Normandie, Caen
Ospedale Policlinico San Martino Irccs Per L Oncologia, Divisione Ematologia Centro Trapianti Di Mid, Genova
Ospedale San Raffaele, Milan
Asst Papa Giovanni Xxiii, Medicina Trasfusionale Ed Ematologia, Bergamo
Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna
Ospedale Maggiore, Ematologia E Centro Trapianti Midollo Osseo (Ctmo), Aou Parma, Parma
Aou Pisana, Stabilimento Di Santa Chiara, Pisa
Chu Hopital Lyon Sud, PierreBenite
Peking University Third Hospital, Beijing
Beijing Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Zhejiang Cancer Hospital, Hangzhou
Fujian Medical University Union Hospital, Fuzhou
Henan Cancer Hospital, Zhengzhou
Sun Yat Sen University Cancer Center, Guangzhou
West China Hospital, Sichuan University, Chengdu
British Columbia Cancer Agency the Vancouver Centre, Vancouver
Azienda Ospedaliera S Maria Di Terni, Terni
Lead Sponsor
BeiGene
INDUSTRY